Biohaven Ltd. Common Shares (NY:BHVN)

12.87 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

April 12, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

April 07, 2025

From Pomerantz LLP

Via GlobeNewswire

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗

April 03, 2025

Via The Motley Fool

Why Biohaven Stock Triumphed on Tuesday ↗

February 11, 2025

Via The Motley Fool

What's Going On With Merus Stock Monday? ↗

January 13, 2025

Merus announced a research collaboration and license agreement with Biohaven.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

April 03, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

March 26, 2025

From Avalo Therapeutics

Via GlobeNewswire

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗

March 04, 2025

Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.

Via Investor's Business Daily

Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy ↗

March 03, 2025

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.

Via Benzinga

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday? ↗

March 03, 2025

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...

Via Benzinga

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines ↗

February 11, 2025

The company could soon add a new, high-value treatment to its portfolio.

Via Investor's Business Daily

Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force ↗

January 26, 2025

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory...

Via Benzinga

Topics Regulatory Compliance

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

January 12, 2025

From Merus N.V.

Via GlobeNewswire

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval ↗

December 17, 2024

Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.

Via Benzinga

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Via Benzinga

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study ↗

November 25, 2024

Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.

Via Benzinga

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy ↗

October 07, 2024

The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 07, 2024

Via Benzinga

Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday ↗

October 01, 2024

Via Benzinga

Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday ↗

September 25, 2024

Via Benzinga

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

September 24, 2024

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

Via MarketBeat

Dow Gains Over 50 Points; Elevai Labs Shares Plummet ↗

September 23, 2024

Via Benzinga

Topics Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Crude Oil Down Over 1%; US Manufacturing PMI Falls In September ↗

September 23, 2024

Via Benzinga

Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise ↗

September 23, 2024

Biohaven announced topline results from its pivotal Study BHV4157-206-RWE, showing that troriluzole significantly slowed disease progression in spinocerebellar ataxia patients over three years. The...

Via Benzinga

Biohaven, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 23, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.